查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1456980

全球體外診斷市場 - 2024 年至 2029 年預測

Global In Vitro Diagnostics Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 124 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

2022年，全球體外診斷市場價值為918.31億美元，預計預測期內複合年成長率為6.17%，到2029年市場總規模將達1396億美元。

體外診斷是對從人體採集的樣本（例如血液或組織）進行測試，以診斷疾病和其他狀況。它還可用於追蹤一個人的整體健康狀況，以幫助治療、治癒或預防疾病。這些測試可以在實驗室、醫療機構或家中進行。測試本身可以在各種設備上執行，從簡單的可攜式設備到複雜的測試設備。這些測試使臨床醫生能夠準確診斷患者並提供適當的治療。

全球 IVD 市場正受益於對照護現場IVD 需求的不斷成長。新推出的體外診斷藥物因其易於使用且高效而受到醫療保健專業人員的歡迎。市面上也有很多市售的診斷套件，例如血糖監測套件。這些套件受到老年人的青睞，因為它們可以最大限度地減少去醫院的次數。

市場促進因素：

  • 慢性病和感染疾病的盛行率以及人口老化：

已開發市場和新興市場不斷成長的老年人口將對體外診斷市場產生積極影響。隨著世界人口老化的迅速增加，與老齡化相關的疾病的盛行率預計將急劇上升。世界其他已開發國家的老年人口也在增加。例如，日本的老年人口與勞動人口的比例最高，其次是德國。據美國醫學會稱，到2030年，65歲以上的人中60%將患有多種慢性病。因此，隨著老年人口的增加，全球各種疾病的盛行率預計將會增加。這被認為是體外診斷藥物市場擴張的主要驅動力。

市場限制因素：

  • 逆贖回

報銷不足是IVD市場擴張的主要障礙。幾年前，美國醫療保險改變了多種體外診斷（包括分子診斷）的報銷方式。一些分子病理學測試沒有自己的醫療通用程序編碼系統 (HCPCS) 代碼，而是使用未發布的代碼申請。在這些情況下，醫療保險行政承包商 (MAC) 會為其當地管轄區設定付款金額。此類變化可能會損害美國分子和基因檢測產業並限制 IVD 市場的成長。

按地區

預計在預測期內，北美將成為體外診斷市場最大的區域市場，並且由於其不斷發展的醫療保健系統和患者醫療保健意識的提高，預計該市場將繼續保持這一地位。促進市場成長的其他因素包括設備的可用性、如何使用設備的知識的增加以及大量患有各種慢性疾病的人口。推動體外診斷市場擴張的另一個因素是北美存在大量主要企業。此外，由於醫療保健成本上升和糖尿病盛行率上升，預計亞太地區在預測期內將以最高成長率擴張。此外，大量需要體外診斷藥物（IVD）測試的慢性疾病患者也促進了亞太市場的成長。

主要進展：

  • 2023 年 5 月 - Thermo Fisher Scientific 和輝瑞將為 30 多個國家（包括拉丁美洲、非洲、中東和亞洲）的肺癌和乳癌患者提供基於次世代定序(NGS) 的試驗的現場訪問。規模。該合作夥伴關係旨在將快速 NGS 測試帶到更接近患者照護端的分散實驗室。 Thermo Fisher 將確定使用其 NGS 技術的當地實驗室，並確保它們擁有必要的基礎設施、訓練有素的員工和品管措施。輝瑞致力於為患者提供負擔得起的 NGS 檢測服務，並提高醫療保健提供者對先進檢測的認知。
  • 2023 年 5 月 - 西門子 Healthineers 推出了 Atellica Hema 570 分析儀和 Atellica Hema 580 分析儀，這兩種大容量血液學檢測系統可消除血液學檢測的工作流程障礙。這些分析儀執行全血球計數 (CBC)，這是實驗室最常執行的診斷測試之一。它具有直覺的介面、自動化、連接性和基於規則的整合測試，可有效解釋複雜的患者結果。這些解決方案可滿足大批量血液學檢測的需求，並確保包含關鍵資訊。
  • 2023 年5 月- 全球女性健康先驅Hologic Inc.（納斯達克股票代碼：HOLX）宣布新近入選的NFL 角衛Kelly Ringo 與其母親、乳腺癌倖存者Tralee Lingo 建立合作關係。 。在美國，女性被診斷出罹患乳癌的頻率較高。

目錄

第1章 簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現
  • CXO觀點

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球體外診斷市場：依技術分類

  • 介紹
  • 免疫檢測
  • 分子診斷
  • 血液學
  • 其他

第6章體外診斷的全球市場：依應用分類

  • 介紹
  • 感染疾病
  • 自體免疫疾病
  • 藥檢
  • 腫瘤學
  • 其他

第7章 全球體外診斷市場：依最終使用者分類

  • 介紹
  • 診斷實驗室
  • 醫院和診所
  • 研究所

第8章全球體外診斷市場：依地區分類

  • 介紹
  • 北美洲
  • 南美洲
  • 歐洲
  • 中東/非洲
  • 亞太地區

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第10章 公司簡介

  • Roche Diagnostics
  • Plasmatec
  • Vitro Bio
  • Omega Diagnostics Group PLC & Technologien GmbH
  • DST Diagnostische Systeme
  • SD Biosensor
  • Abbott Diagnostics
  • Meril Diagnostics
  • NIPPON GENE CO., LTD.
  • Rapid Diagnostics Group of Companies
簡介目錄
Product Code: KSI061611494

The global in-vitro diagnostics market was valued at US$91.831 billion in 2022 and is expected to grow at a CAGR of 6.17% over the forecast period to reach a total market size of US$139.600 billion by 2029.

In-vitro diagnostics are tests performed on samples obtained from the human body, such as blood or tissue, to diagnose illnesses or other conditions. They can also be used to track a person's general health status to assist in curing, treating, or preventing diseases. These tests can be carried out at labs, healthcare institutions, or even at home. The tests themselves may be carried out on a wide range of equipment, from simple portable devices to sophisticated laboratory gear. They enable clinicians to accurately diagnose patients and work to provide suitable treatments.

The global IVD market has benefited from increased demand for point-of-care IVD equipment. The newly released IVD instruments and devices are simple to use and extremely efficient, which has increased their appeal among healthcare practitioners. There are also numerous over-the-counter diagnostic kits on the market, such as glucose monitoring kits. The elderly prefer these kits since they minimize hospital visits.

MARKET DRIVER:

  • Increased prevalence of chronic and infectious diseases, as well as an aging population:

The growing elderly population in both developed and developing regions would have a positive impact on the IVD market. The prevalence of age-related disorders is projected to rise dramatically as the world's aging population grows rapidly. Geriatric populations are likewise substantial and rising in other industrialized economies across the world. Japan, for example, has the highest ratio of the elderly population to the productive population, followed by Germany. According to the American Medical Association, by 2030, it is expected that 60% of people aged 65 and over will have more than one chronic disease. Therefore, the global prevalence of different disorders is anticipated to rise as the geriatric population grows. This is regarded as a major driver for IVD market expansion.

MARKET RESTRAINT:

  • Unfavourable reimbursement

Inadequate reimbursement is a significant roadblock to the IVD market expansion. A few years ago, Medicare in the United States changed the way it reimbursed several IVD tests, including molecular diagnostics. Some molecular pathology tests don't have their own Healthcare Common Procedure Coding System (HCPCS) codes, so they're charged using unlisted codes instead. Medicare Administrative Contractors (MACs) set a payment amount for their local jurisdictions in such instances. These changes are likely to hurt the molecular and genetic testing industry in the United States, thus limiting the IVD market's growth.

By Geography

North America is projected to be the largest regional market for in vitro diagnostics during the forecast period, and it is likely to continue to do so due to its well-developed healthcare system and growing healthcare awareness among patients. Other factors that contribute to the market's growth include the accessibility of devices, increased knowledge about their usage, and the existence of a significant number of populations suffering from different chronic conditions. Another factor driving the in vitro diagnostics market expansion is the presence of a large number of prominent companies in North America. Furthermore, due to an increase in healthcare expenditure and the incidence of diabetes in the area, Asia-Pacific is anticipated to expand at the highest rate throughout the projection period. Possible factors, such as the large population of patients with other chronic illnesses that necessitate IVD testing, also contribute to the Asia-Pacific market's growth.

Key Development:

  • May 2023- Thermo Fisher Scientific and Pfizer have agreed to expand local access to next generation sequencing (NGS)-based testing for lung and breast cancer patients in over 30 countries, including Latin America, Africa, the Middle East, and Asia. The collaboration aims to bring rapid NGS testing to decentralized labs closer to patients' treatment sites. Thermo Fisher will identify local labs using its NGS technology, ensuring they have the necessary infrastructure, trained staff, and quality control measures. Pfizer will work to enable affordable patient access to NGS tests and raise healthcare provider awareness of advanced testing.
  • May 2023- Siemens Healthineers has launched two high-volume hematology test systems, the Atellica Hema 570 Analyzer and the Atellica Hema 580 Analyzer, which remove workflow barriers in hematology testing. These analyzers perform complete blood counts (CBC), which are among the most performed diagnostic tests in laboratories. They offer intuitive interfaces, automation, connectivity, and integrated rules-based testing for efficient interpretation of complex patient results. These solutions address the need for high-volume hematology testing and deliver critical information reliably.
  • May 2023- A global pioneer in women's health, Hologic Inc. (Nasdaq: HOLX) announced a collaboration with NFL cornerback Kelee Ringo, who was recently drafted, and his mother Tralee Hale, a breast cancer survivor, to raise awareness among women about the significance of making yearly mammograms and other critical health screenings a priority. In the United States, women are more frequently diagnosed with breast cancer.

Market Segmentation

By Technique

  • Immunoassay
  • Molecular Diagnostics
  • Hematology
  • Others

By Application

  • Infectious diseases
  • Autoimmune diseases
  • Drug Testing
  • Oncology
  • Others

By End-User

  • Diagnostic Laboratories
  • Hospitals and Clinics
  • Research Laboratories and Institutes

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline
  • 1.8. Key Benefits to the stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

  • 5.1. Introduction
  • 5.2. Immunoassay
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Molecular Diagnostics
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Hematology
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Others
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness

6. GLOBAL IN VITRO DIAGNOSTICS MARKET, BY APPLICATION

  • 6.1. Introduction
  • 6.2. Infectious diseases
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Autoimmune diseases
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Drug Testing
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Oncology
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness
  • 6.6. Others
    • 6.6.1. Market Opportunities and Trends
    • 6.6.2. Growth Prospects
    • 6.6.3. Geographic Lucrativeness

7. GLOBAL IN VITRO DIAGNOSTICS MARKET, BY END-USER

  • 7.1. Introduction
  • 7.2. Diagnostic Laboratories
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Hospitals and Clinicals
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Research Laboratories and Institute
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness

8. GLOBAL IN VITRO DIAGNOSTICS MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Technique
    • 8.2.2. By Application
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. United States
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Technique
    • 8.3.2. By Application
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Technique
    • 8.4.2. By Application
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. Germany
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. France
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Italy
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Spain
        • 8.4.4.5.1. Market Opportunities and Trends
        • 8.4.4.5.2. Growth Prospects
      • 8.4.4.6. Others
        • 8.4.4.6.1. Market Opportunities and Trends
        • 8.4.4.6.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Technique
    • 8.5.2. By Application
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Others
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Technique
    • 8.6.2. By Application
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. Japan
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. China
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. India
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. South Korea
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Taiwan
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Thailand
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Indonesia
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Roche Diagnostics
  • 10.2. Plasmatec
  • 10.3. Vitro Bio
  • 10.4. Omega Diagnostics Group PLC & Technologien GmbH
  • 10.5. DST Diagnostische Systeme
  • 10.6. SD Biosensor
  • 10.7. Abbott Diagnostics
  • 10.8. Meril Diagnostics
  • 10.9. NIPPON GENE CO., LTD.
  • 10.10. Rapid Diagnostics Group of Companies